PaulLWeidenMD

PubMed

• The Art of Medicine: Our Role As Patient Advocates
  Paul L. Weiden> ;Journal of Clinical Oncology. 2012 Nov 1
• 32 citations
  A phase II randomized study comparing sequential and combined intraarterial cisplatin and radiation therapy in primary brain tumors. A Southwest Oncology Group study.
  Joanne E. Mortimer, John Crowley, Harmon J. Eyre, Paul L. Weiden, James R. Eltringham, W. J. Stuckey> ;Cancer. 2010 Aug 2
• 30 citations
  Marrow transplantation for malignant plasma cell disorders: Summary of the Seattle experience*
  C. D. Buckner, Alexander Fefer, William I. Bensinger, R Storb, B. G. Durie, F R Appelbaum, Finn Bo Petersen, Paul L. Weiden, Clift Ra, Jean E. Sanders, Keith M. Sulliv...> ;European Journal of Haematology. Supplementum. 2009 Apr 24
• 4 citations
  Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma
  Howard G. Muntz, T. W. Malpass, Kathryn F. McGonigle, Mandy D. Robertson, Paul L. Weiden> ;Cancer. 2008 Aug 1
• Paclitaxel injectable emulsion: Phase 2a study of weekly administration in patients with non-small cell lung cancer (NSCLC).
  Bogdanova N, Karaseva N, Ognerubov N, Golubeva O, Weiden P> ;J. Clin. Oncol.. 2004-07-15
• Phase II study of intraperitoneal topotecan as consolidation chemotherapy in ovarian cancer.
  Robertson MD, Malpass TW, McGonigle KD, Weiden PL, Muntz H> ;J. Clin. Oncol.. 2004-07-15
• 106 citations
  Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
  Andres Forero, Paul L. Weiden, Julie M. Vose, Susan J. Knox, Albert F. LoBuglio, Jordan Hankins, Michael L. Goris, Vincent J. Picozzi, Don B. Axworthy, Hazel B. Breitz...> ;Blood. 2004 Jul 1
• 5 citations
  Pretargeted radioimmunotherapy (PRIT) using an antibody-streptavidin fusion protein in non-Hodgkin's lymphoma.
  Paul L. Weiden> ;Leukemia & Lymphoma. 2002 Oct 1
• 54 citations
  Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL).
  Paul L. Weiden, Hazel B. Breitz> ;Critical Reviews in Oncology/hematology. 2001 Oct 1
• 146 citations
  Cationic Liposome-Mediated E1A Gene Transfer to Human Breast and Ovarian Cancer Cells and Its Biologic Effects: A Phase I Clinical Trial
  Gabriel N. Hortobagyi, Naoto T. Ueno, Weiya Xia, Shizhen Zhang, J. K. Wolf, Joe B. Putnam, P. L. Weiden, Jie Willey, Mary Carey, D. L. Branham, J. Y. Payne, S. D. Tuck...> ;Journal of Clinical Oncology. 2001 Jul 15
• 5 citations
  High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer
  F. Gutierrez-Delgado, Leona Holmberg, H. Hooper, F R Appelbaum, Robert B. Livingston, Richard T. Maziarz, Paul L. Weiden, S. Rivkin, P. Montgomery, K. Kawahara, Willia...> ;Bone Marrow Transplantation. 2000 Jul 1
• 158 citations
  Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.
  Susan J. Knox, Michael L. Goris, Margaret A. Tempero, Paul L. Weiden, Louis Gentner, Hazel B. Breitz, Gregory P. Adams, Donald B. Axworthy, Sally Gaffigan, Kyle Bryan,...> ;Clinical Cancer Research. 2000 Feb 1
• 110 citations
  Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.
  Paul L. Weiden, Hazel B. Breitz, Oliver W. Press, Janet W. Appelbaum, J. Kyle Bryan, Sally Gaffigan, Diane Stone, Don B. Axworthy, Darrell R. Fisher, John M. Reno> ;Cancer Biotherapy & Radiopharmaceuticals. 2000 Feb 1
• 115 citations
  Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin.
  Hazel B. Breitz, Paul L. Weiden, Paul L. Beaumier, Donald B. Axworthy, Chris Seiler, Fu Min Su, Scott S. Graves, Kyle Bryan, John M. Reno> ;Journal of Nuclear Medicine. 2000 Jan 1
• 9 citations
  Interferon alpha-2a and 13-cis-retinoic acid in patients with metastatic renal cell cancer.
  Andrew Jacobs, Gold Pj, Paul L. Weiden, David M. Aboulafia, Robert H. Rudolph, Vincent J. Picozzi, John A. Thompson> ;Cancer Investigation. 2000 Jan 1
• 51 citations
  Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
  Hazel B. Breitz, Darrell R. Fisher, Michael L. Goris, Susan J. Knox, Barbara A. Ratliff, Albert Murtha, Paul L. Weiden> ;Cancer Biotherapy & Radiopharmaceuticals. 1999 Oct 1
• 10 citations
  Large Cell Non-Hodgkin’s Lymphoma and Hodgkin’s Disease Arising Synchronously in a Patient With Chronic Lymphocytic Leukemia: Importance of Immunocytochemistry
  Ajay K. Gopal, Scott M. Schuetze, David G. Maloney, Paul L. Weiden> ;Blood. 1999 Oct 1
• 27 citations
  High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer.
  Leona Holmberg, Taner Demirer, S Rowley, Buckner Cd, G Goodman, R. T. Maziarz, J Klarnet, N Zuckerman, G Harrer, R McCloskey, R Gersh, R Goldberg, W Nichols, A Jacobs,...> ;Bone Marrow Transplantation. 1998 Oct 1
• 24 citations
  Factor V Leiden mutation does not account for central venous catheter-related thrombosis.
  Michele Riordan, Paul L. Weiden> ;American Journal of Hematology. 1998 Jun 1
• 4 citations
  An Asian man with enlarged glands
  Paul L Weiden, Donald E. Bauermeister, Ernest A Fatta> ;Lancet. 1998 Apr 11
• 16 citations
  Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation
  Chien-Shing Chen, Kristy Seidel, James O. Armitage, Joseph W. Fay, Frederick R. Appelbaum, Mary M. Horowitz, Elizabeth J. Shpall, Paul L. Weiden, Karen H. Antman, Rich...> ;Biology of Blood and Marrow Transplantation. 1997 Dec 1
• 29 citations
  Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy.
  Hazel B. Breitz, Andrea Tyler, Michael J. Bjorn, Terry Lesley, Paul L. Weiden> ;Clinical Nuclear Medicine. 1997 Sep 1
• 28 citations
  High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer.
  William I. Bensinger, Kathy Schiffman, Leona Holmberg, F R Appelbaum, R. T. Maziarz, P. Montgomery, E Ellis, Saul E. Rivkin, Paul L. Weiden, K Lilleby, S Rowley, Steph...> ;Bone Marrow Transplantation. 1997 Jun 1
• 15 citations
  Concomitant Intraarterial Cisplatin, Intravenous 5-Fluorouracil, and Split-Course Radiation Therapy for Locally Advanced Unresectable Pancreatic Adenocarcinoma: A Phas...
  Charles R. Thomas, Paul L. Weiden, L. Traverso, Tove Thompson> ;American Journal of Clinical Oncology. 1997 Apr 1
• 47 citations
  Syngeneic marrow transplantation in patients with multiple myeloma.
  William I. Bensinger, Taner Demirer, Buckner Cd, F R Appelbaum, R Storb, K Lilleby, Paul L. Weiden, A Z Bluming, A Fefer> ;Bone Marrow Transplantation. 1996 Sep 1
• Join now to see all

Journal Articles

• Art of Oncology: Our Role as Patient Advocate  
  Weiden PL, J Clin Oncol, 1/1/2012
• Phase II study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma  
  Muntz HG, Malpass TW, McGonigle KF, Robertson MD, and Weiden PL, Cancer, 1/1/2008
• Phase I trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin’s lymphoma.  
  Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins J, Goris ML, Picozzi VJ, Axworthy DB, Breitz HB, Sims RB, Ghalie RG, Shen S, and Meredith RF, Blood, 1/1/2004
•  
  Weiden PL, Leukemia and Lymphoma, 1/1/2002
•  
  Weiden PL, Breitz HB, Crit Rev Oncol Hematol, 1/1/2001
• Interpreting Key Trials--Breast Cancer prevention: Incorporating emerging data into evidence-based practice.  
  Goetsch CM, Weiden PL, Virginia Mason Medical Center Bulletin, 1/1/2001
• Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial.  
  Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, ..., J Clin Oncol, 1/1/2001
• Clinical optimization of pretargeted immunotherapy (PRITTM) with antibody-streptavidin conjugate and 90Y-DOTA-biotin.  
  Breitz HB, Weiden PL, Beaumier PL, Axworthy DB, Seiler C, Su F-M, Graves S, Bryan K, Reno JM, J Nucl Med, 1/1/2000
• Pretargeted radioimmunotherapy (PRITTM) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.  
  Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Stone D, Axworthy D, Fisher D, Reno J, Cancer Biother Radiopharm, 1/1/2000
• Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.  
  Knox SJ, Goris ML, Weiner LM, Tempero M, Weiden PL, Gentner L, Breitz H, Axworthy D, Seiler C, Bryan K, Fisher DR, Horak ID, Clin Cancer Res, 1/1/2000
• Interferon alpha-2a and 13-cis-retinoic acid in patients with metastatic renal cell cancer.  
  Jacobs A, Gold P, Weiden P, Aboulafia D, Rudolph R, Picozzi V, Thompson J, Cancer Invest, 1/1/2000
• High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer.  
  Gutierrez-Delgado F, Holmberg LA, Hooper H, Appelbaum FR, Livingston RB, Maziarz RT, Weiden P, Rivkin S, Montgomery P, Kawahara K, Bensinger W, Bone Marrow Transplant, 1/1/2000
• Large cell non-Hodgkin's lymphoma and Hodgkin's disease arising synchronously in a patient with chronic lymphocytic leukemia: Importance of immunocytochemistry [letter].  
  Gopal AK, Schuetze SM, Maloney DG, Weiden PL, Blood, 1/1/1999
• Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/SA.  
  Breitz HB, Fisher DR, Goris ML, Knox S, Ratliff B, Weiden PL, Cancer Biotherapy and Radiopharm, 1/1/1999
• Initial control of chemotherapy-induced nausea and vomiting in patient quality of life.  
  Morrow GR, Roscoe JA, Hickok JT, Stern RM, Pierce HI, King DB, Banerjee TK, Weiden P, Oncology, 3/1/1998
• Factor V Leiden mutation does not account for central venous catheter-related thrombosis.  
  Riordan M, Weiden PL, Am J Hematol, 1/1/1998
• An Asian man with enlarged glands.  
  Weiden PL, Bauermeister DE, Fatta EA, Lancet, 1/1/1998
• Marantic endocarditis.  
  Weiden PL, MacLean JL, Gibbons EF, Virginia Mason Bull, 1/1/1998
• High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cells (PBSC) rescue in patients with advanced stage III/IV ovarian cancer.  
  Holmberg LA, Demirer T, Rowley S, Buckner CD, Goodman G, Maziarz R, Klarnet J, Zuckerman N, Harrer G, McCloskey R, Gersh R, Goldberg R, Nichols W, Jacobs A, Weiden P, ..., Bone Marrow Transplant, 1/1/1998
• Concomitant intra-arterial cisplatin, intravenous 5-fluorouracil, and split-course radiation therapy for locally advanced unresectable pancreatic adenocarcinoma: a pha...  
  Thomas CR, Jr., Weiden PL, Traverso LW, Thompson T, Am J Clin Oncol, 1/1/1997
• High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer.  
  Bensinger WI, Schiffman KS, Holmberg L, Appelbaum FR, Maziarz R, Montgomery P, Rivkin S, Weiden P, Lilleby K, Rowley S, Petersdorf S, Klarnet JP, Nichols W, Hertler A,..., Bone Marrow Transplant, 1/1/1997
• Venous thrombosis and activated protein C resistance.  
  Weiden PL, Virginia Mason Bull, 1/1/1997
• Kimura disease: an uncommon syndrome of reactive lymphadenopathy.  
  Weiden PL, Bauermeister DE, Virginia Mason Bull, 1/1/1997
•  
  Breitz HB, Tyler A, Bjorn MJ, Lesley T, Weiden PL, Clin Nuclear Med, 1/1/1997
• Safeguarding the administration of high-dose chemotherapy: A national practice survey by the American Society for Blood and Marrow Transplantation.  
  Chen CS, Seidel K, Armitage JO, Fay JW, Appelbaum FR, Horowitz MM, Shpall EJ, Weiden PL, Antman KS, Champlin RE, Kersey JH, Sullivan KM, Biol Blood Marrow Transplant, 1/1/1997
• Join now to see all

Books/Book Chapters

• Radioimmunotherapy in the treatment of non-Hodgkin's lymphoma. 
  Krieger MS, Weiden P, Press O, DeNardo GL, Breitz HEditors: Fritzberg AR, Abrams P.Marcel Dekker, New York, NY2000
• Radioimmunotherapy of solid tumors. 
  Breitz HB, Weiden PL, Beaumier PLEditors: Fritzberg AR, Abrams P.Marcel Dekker, New York, NY1999
• Gastrointestinal Oncology 
  Chapter: Chapter 41. Monoclonal antibodies in the imaging and treatment of gastrointestinal malignancies. 
  Page 579 - 591Fer MF, Abrams PG, Ahlgren JD, Weiden PLEditors: Ahlgren JD, Macdonald JS.JB Lippincott, Philadelphia1992
• Aplastic Anemia and Other Bone Marrow Failure Syndromes. 
  Chapter: Long-term comparison of immunosuppressive therapy with antithymocyte globulin to bone marrow transplantation in aplastic anemia 
  Page 104 - 114Doney K, Kopecky K, Storb R, Buckner CD, Singer J, Anasetti C, Appelbaum F, Beatty P, Bensinger W, Berenson R, Clift R, Deeg HJ, Hansen J, Hill R, Loughran T, Martin P...Editors: Shahidi NT.Springer-Verlag, New York, Berlin, Heidelberg, London, Paris, Tokyo1990
• Acute Myelogenous Leukemia, UCLA Symposia on Molecular and Cellular Biology. 
  Chapter: Graft-versus-leukemia effect of allogeneic bone marrow transplantation in patients with acute nonlymphocytic leukemia 
  Page 391 - 401Sullivan KM, Weiden PL, Fefer A, Appelbaum FR, Anasetti C, Buckner CD, Clift R, Doney K, Fisher L, Martin P, Petersen F, Sanders J, Singer J, Stewart P, Witherspoon RP...Editors: Gale RP.Wiley-Liss, Inc., New York1990
• Graft Versus Host Disease: Research and Clinical Management. 
  Chapter: Graft-versus-leukemia effects in clinical bone marrow transplantation, Chapter 39 
  Page 691 - 708Weiden PL, Horowitz MMEditors: Burakoff SJ, Ferrara J, Deeg HJ, Atkinson K.Marcel Dekker, Inc., New York1989
• Cellular Immunotherapy of Cancer 
  Chapter: Graft-versus-leukemia effect in man: The relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation 
  Page 401 - 408Fefer A, Sullivan KM, Weiden P, Buckner CD, Schoch G, Storb R, Thomas EDEditors: Truitt RL, Gale RP, Bortin MM.Alan R. Liss, Inc., New York1987
• Cellular Immunotherapy of Cancer 
  Chapter: Graft-versus-leukemia in man: Relationship of acute and chronic graft-versus-host disease to relapse of acute leukemia following allogeneic bone marrow transplantation 
  Page 391 - 399Sullivan KM, Fefer A, Witherspoon R, Storb R, Buckner CD, Weiden P, Schoch G, Thomas EDEditors: Truitt RL, Gale RP, Bortin MM.Alan R. Liss, Inc., New York1987
• Adjuvant Therapy of Cancer 
  Chapter: Neoadjuvant chemoradiotherapy for resectable gastroesophageal junction adenocarcinoma 
  Page 497 - 505Weiden PL, Hill LD, Kozarek RA, Hafermann MD, Ryan JA, Patterson DJEditors: Salmon SE.V. Grune & Stratton, Orlando1987
• Head and Neck Management of the Cancer Patient. 
  Chapter: Principles of chemotherapy, Chapter 6 
  Page 83 - 99Weiden PLEditors: Peterson DE, Elias EG, Senis ST.Martinus Nijhoff, The Hague, Netherlands1986
• The Pathology of Bone Marrow Transplantation 
  Chapter: Human marrow transplantation: An overview 
  Page 1 - 10Weiden PL, Sale GE, Shulman HMEditors: Sale GE, Shulman HM.Masson Publishing USA, New York1984
• Critical Reviews in Clinical Laboratory Sciences. Fall 1983, vol 19 
  Chapter: Allogeneic bone marrow transplantation 
  Page 173 - 186Weiden PLEditors: Batsakis J, Savory J.CRC Press, Inc., Boca Raton, FL1983
• Experimental Hematology Today 
  Chapter: Long-term survival of dogs given marrow grafts from unrelated DLA-nonidentical donors and treated with Cyclosporin A and methotrexate--Is tolerance mediated by suppressor cells 
  Page 127 - 133Deeg HJ, Storb R, Raff RF, Weiden PL, Atkinson K, Thomas EDEditors: Baum SJ, Ledney GD, Thierfelder S.1982
• Experimental Hematology Today 
  Chapter: Rejection of DLA-identical canine littermate marrow after transfusion-induced sensitization: Antigens involved are expressed on cotton-wool adherent but not on nonadherent mononuclear cells, granuloc 
  Page 31 - 37Deeg HJ, Torok-Storb B, Storb R, Weiden PL, DeRose S, Graham TC, Atkinson K, Thomas EdEditors: Baum SJ, Ledney GD, Khan A, Basel S, Karger.1981
• Cancer: Achievements, Challenges and Prospects for the 1980s. 
  Chapter: Graft-versus-host disease, immunologic reconstitution and graft-host tolerance in marrow graft recipients 
  Page 639 - 658Storb R, Atkinson K, Lum LG, Sullivan KM, Tsoi MS, Weiden PL, Witherspoon RPEditors: Burchenal JH, Oettgen HF.Grune Stratton, New York1981
• Graft-Versus-Leukemia in Man and Animal Models. 
  Chapter: Antitumor effect of marrow transplantation in randomly bred species: Studies in dogs with spontaneous lymphoma 
  Page 127 - 138Weiden PL, Storb R, Deeg HJEditors: Okunewick J, Meredith R.CRC Press, Boca Raton, FL1981
• Graft-Versus-Leukemia in Man and Animal Models 
  Chapter: Antitumor effect of marrow transplantation in human recipients of syngeneic or allogeneic grafts 
  Page 11 - 23Weiden PL, Flournoy N, Thomas ED, Fefer A, Storb REditors: Okunewick J, Meredith R.CRC Press, Inc., Boca Raton, FL1981
• Immunobiology of Bone Marrow Transplantation. 
  Chapter: Marrow graft studies in dogs 
  Page 43 - 52Storb R, Weiden PL, Deeg HJ, Torok-Storb B, Atkinson K, Graham TC, and Thomas EDEditors: Thierfelder S, Rodt H, Kolb HJ.Springer-Verlag, Heidelberg1980
• Biology of Bone Marrow Transplantation. ICN-UCLA Symposia on Molecular and Cellular Biology, Vol. XVII 
  Chapter: Graft-versus-host disease in allogeneic marrow transplantation 
  Page 37 - 48Weiden PL, and the Seattle Marrow Transplant TeamEditors: Gale RP, Fox CF.Academic Press, New York1980
• Biology of Bone Marrow Transplantation. 
  Chapter: The spectrum of chronic graft-vs-host disease in man 
  Page 69 - 73Sullivan KM, Shulman HM, Weiden PL, Storb R, Tsoi MS, Thomas EDEditors: Gale RP, Fox CF.Academic Press, New York1980
• Biology of Bone Marrow Transplantation. 
  Chapter: Cyclosporin A in marrow transplantation in the dog 
  Page 281 - 284Deeg HJ, Storb R, Weiden PL, Graham T, Thomas EDEditors: Gale RP, Fox CF.Academic Press, New York1980
• Biology of Bone Marrow Transplantation 
  Chapter: Studies on transplantation tolerance in canine radiation chimeras 
  Page 271 - 280Atkinson K, Storb R, Weiden PL, Deeg HJ, Kopecky KJ, Graham TC, Thomas EDEditors: Gale RP, Fox CF.Academic Press, New York1980
• Experimental Hematology Today 
  Chapter: Lymphocyte/marrow co-cultures as a tool to detect transfusion-induced sensitization and predict marrow graft rejection in dogs 
  Page 257 - 261Torok-Storb BJ, Storb R, Deeg HJ, Graham TC, Wise CM, Weiden PL, Adamson JWEditors: Baum SJ, Ledney GD.Springer-Verlag, New York1979
• Experimental Hematology Today. 
  Chapter: Engraftment of HLA-identical marrow in treatment of severe aplastic anemia: Results of 110 consecutive transplants 
  Page 151 - 156Storb R, Thomas ED, Weiden PL, Buckner CD, Clift RA, Fefer A, Goodell BW, Johnson FL, Neiman PE, Sanders JE, Singer JEditors: Baum SJ, Ledney GD.Springer-Verlag, New York1978
• Experimental Hematology Today. 
  Chapter: Marrow transplantation for acute leukemia 
  Page 191 - 194Buckner CD, Clift RA, Fefer A, Neiman PE, Sanders JE, Storb R, Weiden PL, Thomas ED and the Seattle Marrow Transplant TeamEditors: Baum SJ, Ledney GD.Springer-Verlag, New York1978
• Join now to see all

Abstracts/Posters

• Interstitial pneumonia and opportunistic viral infection following marrow transplantation for acute leukemia and aplastic anemia.
  Nieman PE, Reeves W, Ray G, Buckner CD, Storb R, Clift RA, Weiden PL, Fefer A, and Thomas ED, International Society of Blood Transfusion Symposium on Human Bone Marrow Transplantation., San Francisco, CA, 11/1/1976